Relmada Therapeutics, Inc. (RLMD) Social Stream
Relmada Therapeutics Inc (RLMD) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Relmada Therapeutics Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 49 weeks, RLMD's average price target has gone up $3.57.
RLMD reports an average of 130.49% for its upside potential over the past 47 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
RLMD Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Relmada Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 275.26% of them.
- To contextualize these metrics, consider that out of all US stocks, Relmada Therapeutics Inc's variance in analysts' estimates is lower than -138.14% of them.
- RLMD has a greater average analyst price target than 283.02% of stocks in the small market cap category.
- In the context of Healthcare stocks, Relmada Therapeutics Inc's number of analysts covering the stock is higher than 105.8% of them.
In the Pharmaceutical Products industry, RIGL, RGLS, and REPH are the three stocks most similar to Relmada Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding RLMD using the data that counts. Try POWR Ratings for free.